Michael B. Jordan, MD

PRMT5 inhibition reduces hyperinflammation in a murine model of secondary hemophagocytic lymphohistiocytosis. Brown-Burke, F; Saadey, R; Mao, HC; Marra, P; Brooks, E; Wandtke, A; Hout, I; Leon, S; Sharma, A; Yasin, A; Chen, C; Jordan, MB; Baiocchi, RA; Shindiapina, P. Blood Advances. 2025; 9:2379-2392.

T Cell Tropic Epstein Barr Virus in a Patient with Hemophagocytic Lymphohistiocytosis. Wozny, N; Niebur, H; Jordan, M. 2025; 1.

Vitamin D Deficiency Is Prevalent and Resistant to Correction in Patients with Hemophagocytic Lymphohistiocytosis. Jess, J; Verkamp, B; Jordan, M. 2025; 1.

Precision Alemtuzumab Dosing Results in Day 0 Target Range Achievement in 80% of IEI Patients and Minimizes Risks of GVHD, Clinically Significant Mixed Chimerism, and Secondary Graft Failure. Marsh, R; Khoury, R; Mizuno, K; Hosawi, A; Cottrell, C; Nguyen, E; Landon, B; Chandra, S; Jordan, M; Kumar, A; Bleesing, J; Davies, S; Moore, C; Mehta, P. 2025; 1.

Addition of Thiotepa to Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Reduces Secondary Graft Failure in Allogeneic HSCT for Inborn Errors of Immunity. Khoury, R; Jordan, M; Bleesing, J; Kumar, A; Saldana, BD; Verkamp, B; Davies, S; Marsh, R; Chandra, S. 2025; 1.

Malignancy-associated HLH: mechanisms, diagnosis, and treatment of a severe hyperinflammatory syndrome. Zoref-Lorenz, A; Witzig, TE; Cerhan, JR; Jordan, MB. Leukemia and Lymphoma. 2025; 66:628-636.

EBV-Associated T/NK-LPD Manifesting As HLH Cured By Nivolumab and Emapalumab, Avoiding the Need for Allogeneic HCT. Cook, E; Haacker, L; Chandra, S; Jordan, MB; Verkamp, B; McCarthy, L; Rotz, SJ; Hammoud, MS; Pariury, H; McKeone, D; Kumar, A. Transplantation and Cellular Therapy. 2025; 31:s43.

Transplant Related Outcomes in Patients with Hemophagocytic Lymphohistiocytosis Treated with Emapalumab As a Bridge to Hematopoietic Stem Cell Transplantation (HSCT): The Real-HLH Study. Allen, C; Chandrakasan, S; Jordan, MB; Leiding, JW; Marrone, M; Oladapo, A; Pednekar, P; Walkovich, K; Yee, J. Transplantation and Cellular Therapy. 2025; 31:s163-s164.

Exploring PRMT5 Inhibition As a Therapeutic Strategy in Primary and Secondary Hemophagocytic Lymphohistiocytosis. Steyn, S; Brown-Burke, F; Marra, P; Chen, C; Saadey, R; Mao, C; Weist, J; Klimaszewski, H; Hout, I; Leon, S; Vaddi, K; Jordan, MB; Baiocchi, R; Shindiapina, P. Transplantation and Cellular Therapy. 2025; 31:s159.

Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study. Chandrakasan, S; Allen, CE; Bhatla, D; Carter, J; Chien, M; Cooper, R; Draper, L; Eckstein, OS; Hanna, R; Hays, JA; Riskalla, M; Hobday, P; Baker, A; Ward, B. Arthritis and Rheumatology. 2025; 77:226-238.